Global Cancer Immunotherapy Market Report 2024, with Revenue Forecasts to 2034 for Five Regional and 25 Key National Markets
27 juin 2024 07h02 HE
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Cancer Immunotherapy Market is...
$7 Bn House Dust Mite Allergy Global Market Opportunities and Strategies to 2033 - Innovative AI-Powered Allergy Testing Revolutionizes Market Dynamics
26 juin 2024 06h22 HE
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "House Dust Mite Allergy Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.The global...
Global KRAS Inhibitors Market & Clinical Trials Future Market Outlook 2030: 2 Approved KRAS Inhibitors and 90+ Drugs KRAS Inhibitors in Clinical Trials
20 juin 2024 06h59 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030" report has been added to ResearchAndMarkets.com's offering. With the...
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
18 juin 2024 15h17 HE
|
Tevogen Bio Inc
Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
17 juin 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
Tevogen Bio Set to Join Russell 3000® Index
12 juin 2024 15h45 HE
|
Tevogen Bio Inc
Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
11 juin 2024 15h30 HE
|
Tevogen Bio Inc
Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.
Trispecific Antibodies Set to Transform the Future of Immunotherapy: Trispecific Antibodies Clinical Trials Insight by Company, Country, Indication & Phase
07 juin 2024 02h59 HE
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering. The blueprint...
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
06 juin 2024 15h52 HE
|
Tevogen Bio Inc
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
06 juin 2024 11h15 HE
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.